ANDAORALTABLET
Approved
Mar 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LOPINAVIR AND RITONAVIR (lopinavir and ritonavir) by AbbVie is hiv protease inhibitors [moa]. First approved in 2022.
Drug data last refreshed 19h ago
Mechanism of Action
HIV Protease Inhibitors
Pharmacologic Class:
Protease Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
AbbVie
NORTH CHICAGO, IL
Worked on LOPINAVIR AND RITONAVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.